nodes	percent_of_prediction	percent_of_DWPC	metapath
Metolazone—Neuropathy peripheral—Fludarabine—lymphatic system cancer	0.00684	0.00684	CcSEcCtD
Metolazone—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.00673	0.00673	CcSEcCtD
Metolazone—Epistaxis—Fludarabine—lymphatic system cancer	0.00658	0.00658	CcSEcCtD
Metolazone—Swelling—Carmustine—lymphatic system cancer	0.00657	0.00657	CcSEcCtD
Metolazone—Anorexia—Mechlorethamine—lymphatic system cancer	0.00655	0.00655	CcSEcCtD
Metolazone—Chills—Teniposide—lymphatic system cancer	0.0064	0.0064	CcSEcCtD
Metolazone—Swelling—Mitoxantrone—lymphatic system cancer	0.00611	0.00611	CcSEcCtD
Metolazone—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00597	0.00597	CcSEcCtD
Metolazone—Erythema multiforme—Fludarabine—lymphatic system cancer	0.00592	0.00592	CcSEcCtD
Metolazone—Hyponatraemia—Carmustine—lymphatic system cancer	0.00582	0.00582	CcSEcCtD
Metolazone—Anaemia—Teniposide—lymphatic system cancer	0.00574	0.00574	CcSEcCtD
Metolazone—Agitation—Teniposide—lymphatic system cancer	0.0057	0.0057	CcSEcCtD
Metolazone—Chills—Fludarabine—lymphatic system cancer	0.00562	0.00562	CcSEcCtD
Metolazone—Hyponatraemia—Vincristine—lymphatic system cancer	0.00556	0.00556	CcSEcCtD
Metolazone—Leukopenia—Teniposide—lymphatic system cancer	0.00555	0.00555	CcSEcCtD
Metolazone—Hyponatraemia—Mitoxantrone—lymphatic system cancer	0.00541	0.00541	CcSEcCtD
Metolazone—Hypertension—Teniposide—lymphatic system cancer	0.00536	0.00536	CcSEcCtD
Metolazone—Chest pain—Teniposide—lymphatic system cancer	0.00528	0.00528	CcSEcCtD
Metolazone—Hypokalaemia—Carmustine—lymphatic system cancer	0.00527	0.00527	CcSEcCtD
Metolazone—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00506	0.00506	CcSEcCtD
Metolazone—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.00506	0.00506	CcSEcCtD
Metolazone—Anaemia—Fludarabine—lymphatic system cancer	0.00504	0.00504	CcSEcCtD
Metolazone—Agitation—Fludarabine—lymphatic system cancer	0.00501	0.00501	CcSEcCtD
Metolazone—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00496	0.00496	CcSEcCtD
Metolazone—Malaise—Fludarabine—lymphatic system cancer	0.00492	0.00492	CcSEcCtD
Metolazone—Hypokalaemia—Mitoxantrone—lymphatic system cancer	0.0049	0.0049	CcSEcCtD
Metolazone—Leukopenia—Fludarabine—lymphatic system cancer	0.00488	0.00488	CcSEcCtD
Metolazone—Pruritus—Mechlorethamine—lymphatic system cancer	0.00486	0.00486	CcSEcCtD
Metolazone—Anorexia—Teniposide—lymphatic system cancer	0.00483	0.00483	CcSEcCtD
Metolazone—Cough—Fludarabine—lymphatic system cancer	0.00476	0.00476	CcSEcCtD
Metolazone—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.0047	0.0047	CcSEcCtD
Metolazone—Arthralgia—Fludarabine—lymphatic system cancer	0.00464	0.00464	CcSEcCtD
Metolazone—Discomfort—Fludarabine—lymphatic system cancer	0.00459	0.00459	CcSEcCtD
Metolazone—Hyperglycaemia—Carmustine—lymphatic system cancer	0.00452	0.00452	CcSEcCtD
Metolazone—Petechiae—Methotrexate—lymphatic system cancer	0.0045	0.0045	CcSEcCtD
Metolazone—Erectile dysfunction—Vincristine—lymphatic system cancer	0.0044	0.0044	CcSEcCtD
Metolazone—Decreased appetite—Teniposide—lymphatic system cancer	0.0044	0.0044	CcSEcCtD
Metolazone—Neuropathy peripheral—Carmustine—lymphatic system cancer	0.00438	0.00438	CcSEcCtD
Metolazone—Vomiting—Mechlorethamine—lymphatic system cancer	0.00437	0.00437	CcSEcCtD
Metolazone—Photosensitivity reaction—Vincristine—lymphatic system cancer	0.00436	0.00436	CcSEcCtD
Metolazone—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00436	0.00436	CcSEcCtD
Metolazone—Rash—Mechlorethamine—lymphatic system cancer	0.00433	0.00433	CcSEcCtD
Metolazone—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00433	0.00433	CcSEcCtD
Metolazone—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.00429	0.00429	CcSEcCtD
Metolazone—Anorexia—Fludarabine—lymphatic system cancer	0.00424	0.00424	CcSEcCtD
Metolazone—Hyperglycaemia—Mitoxantrone—lymphatic system cancer	0.0042	0.0042	CcSEcCtD
Metolazone—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.00418	0.00418	CcSEcCtD
Metolazone—Feeling abnormal—Teniposide—lymphatic system cancer	0.00417	0.00417	CcSEcCtD
Metolazone—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00415	0.00415	CcSEcCtD
Metolazone—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00414	0.00414	CcSEcCtD
Metolazone—Chills—Bleomycin—lymphatic system cancer	0.00412	0.00412	CcSEcCtD
Metolazone—Nausea—Mechlorethamine—lymphatic system cancer	0.00408	0.00408	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00406	0.00406	CcSEcCtD
Metolazone—Urticaria—Teniposide—lymphatic system cancer	0.00402	0.00402	CcSEcCtD
Metolazone—Abdominal pain—Teniposide—lymphatic system cancer	0.004	0.004	CcSEcCtD
Metolazone—Paraesthesia—Fludarabine—lymphatic system cancer	0.004	0.004	CcSEcCtD
Metolazone—Hyperuricaemia—Methotrexate—lymphatic system cancer	0.00399	0.00399	CcSEcCtD
Metolazone—Dyspepsia—Fludarabine—lymphatic system cancer	0.00392	0.00392	CcSEcCtD
Metolazone—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00387	0.00387	CcSEcCtD
Metolazone—Decreased appetite—Fludarabine—lymphatic system cancer	0.00387	0.00387	CcSEcCtD
Metolazone—Fatigue—Fludarabine—lymphatic system cancer	0.00384	0.00384	CcSEcCtD
Metolazone—Constipation—Fludarabine—lymphatic system cancer	0.00381	0.00381	CcSEcCtD
Metolazone—Pain—Fludarabine—lymphatic system cancer	0.00381	0.00381	CcSEcCtD
Metolazone—Blood uric acid increased—Methotrexate—lymphatic system cancer	0.00377	0.00377	CcSEcCtD
Metolazone—Hypersensitivity—Teniposide—lymphatic system cancer	0.00373	0.00373	CcSEcCtD
Metolazone—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00373	0.00373	CcSEcCtD
Metolazone—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00371	0.00371	CcSEcCtD
Metolazone—Anaemia—Bleomycin—lymphatic system cancer	0.0037	0.0037	CcSEcCtD
Metolazone—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00367	0.00367	CcSEcCtD
Metolazone—Asthenia—Teniposide—lymphatic system cancer	0.00363	0.00363	CcSEcCtD
Metolazone—Malaise—Bleomycin—lymphatic system cancer	0.00361	0.00361	CcSEcCtD
Metolazone—Pruritus—Teniposide—lymphatic system cancer	0.00358	0.00358	CcSEcCtD
Metolazone—Leukopenia—Bleomycin—lymphatic system cancer	0.00358	0.00358	CcSEcCtD
Metolazone—Skin exfoliation—Methotrexate—lymphatic system cancer	0.00353	0.00353	CcSEcCtD
Metolazone—Cough—Bleomycin—lymphatic system cancer	0.00349	0.00349	CcSEcCtD
Metolazone—Diarrhoea—Teniposide—lymphatic system cancer	0.00347	0.00347	CcSEcCtD
Metolazone—Chest pain—Bleomycin—lymphatic system cancer	0.0034	0.0034	CcSEcCtD
Metolazone—Back pain—Carmustine—lymphatic system cancer	0.00338	0.00338	CcSEcCtD
Metolazone—Discomfort—Bleomycin—lymphatic system cancer	0.00336	0.00336	CcSEcCtD
Metolazone—Chills—Mitoxantrone—lymphatic system cancer	0.00334	0.00334	CcSEcCtD
Metolazone—Vision blurred—Carmustine—lymphatic system cancer	0.00329	0.00329	CcSEcCtD
Metolazone—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00328	0.00328	CcSEcCtD
Metolazone—Anaemia—Carmustine—lymphatic system cancer	0.00323	0.00323	CcSEcCtD
Metolazone—Back pain—Vincristine—lymphatic system cancer	0.00322	0.00322	CcSEcCtD
Metolazone—Vomiting—Teniposide—lymphatic system cancer	0.00322	0.00322	CcSEcCtD
Metolazone—Agitation—Carmustine—lymphatic system cancer	0.00321	0.00321	CcSEcCtD
Metolazone—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.0032	0.0032	CcSEcCtD
Metolazone—Asthenia—Fludarabine—lymphatic system cancer	0.00319	0.00319	CcSEcCtD
Metolazone—Rash—Teniposide—lymphatic system cancer	0.00319	0.00319	CcSEcCtD
Metolazone—Dermatitis—Teniposide—lymphatic system cancer	0.00319	0.00319	CcSEcCtD
Metolazone—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00318	0.00318	CcSEcCtD
Metolazone—Headache—Teniposide—lymphatic system cancer	0.00317	0.00317	CcSEcCtD
Metolazone—Pruritus—Fludarabine—lymphatic system cancer	0.00315	0.00315	CcSEcCtD
Metolazone—Back pain—Mitoxantrone—lymphatic system cancer	0.00314	0.00314	CcSEcCtD
Metolazone—Leukopenia—Carmustine—lymphatic system cancer	0.00312	0.00312	CcSEcCtD
Metolazone—Anorexia—Bleomycin—lymphatic system cancer	0.00311	0.00311	CcSEcCtD
Metolazone—Anaemia—Vincristine—lymphatic system cancer	0.00308	0.00308	CcSEcCtD
Metolazone—Agitation—Vincristine—lymphatic system cancer	0.00306	0.00306	CcSEcCtD
Metolazone—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00306	0.00306	CcSEcCtD
Metolazone—Photosensitivity—Methotrexate—lymphatic system cancer	0.00306	0.00306	CcSEcCtD
Metolazone—Diarrhoea—Fludarabine—lymphatic system cancer	0.00305	0.00305	CcSEcCtD
Metolazone—Hypertension—Carmustine—lymphatic system cancer	0.00301	0.00301	CcSEcCtD
Metolazone—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00301	0.00301	CcSEcCtD
Metolazone—Nausea—Teniposide—lymphatic system cancer	0.00301	0.00301	CcSEcCtD
Metolazone—Anaemia—Mitoxantrone—lymphatic system cancer	0.003	0.003	CcSEcCtD
Metolazone—Vertigo—Vincristine—lymphatic system cancer	0.00299	0.00299	CcSEcCtD
Metolazone—Leukopenia—Vincristine—lymphatic system cancer	0.00298	0.00298	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00297	0.00297	CcSEcCtD
Metolazone—Chest pain—Carmustine—lymphatic system cancer	0.00297	0.00297	CcSEcCtD
Metolazone—Anxiety—Carmustine—lymphatic system cancer	0.00296	0.00296	CcSEcCtD
Metolazone—Paraesthesia—Bleomycin—lymphatic system cancer	0.00293	0.00293	CcSEcCtD
Metolazone—Malaise—Mitoxantrone—lymphatic system cancer	0.00293	0.00293	CcSEcCtD
Metolazone—Leukopenia—Mitoxantrone—lymphatic system cancer	0.0029	0.0029	CcSEcCtD
Metolazone—Hypertension—Vincristine—lymphatic system cancer	0.00288	0.00288	CcSEcCtD
Metolazone—Decreased appetite—Bleomycin—lymphatic system cancer	0.00284	0.00284	CcSEcCtD
Metolazone—Cough—Mitoxantrone—lymphatic system cancer	0.00283	0.00283	CcSEcCtD
Metolazone—Vomiting—Fludarabine—lymphatic system cancer	0.00283	0.00283	CcSEcCtD
Metolazone—Rash—Fludarabine—lymphatic system cancer	0.00281	0.00281	CcSEcCtD
Metolazone—Dermatitis—Fludarabine—lymphatic system cancer	0.0028	0.0028	CcSEcCtD
Metolazone—Hypertension—Mitoxantrone—lymphatic system cancer	0.0028	0.0028	CcSEcCtD
Metolazone—Pain—Bleomycin—lymphatic system cancer	0.00279	0.00279	CcSEcCtD
Metolazone—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00279	0.00279	CcSEcCtD
Metolazone—Headache—Fludarabine—lymphatic system cancer	0.00279	0.00279	CcSEcCtD
Metolazone—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00276	0.00276	CcSEcCtD
Metolazone—Chest pain—Mitoxantrone—lymphatic system cancer	0.00276	0.00276	CcSEcCtD
Metolazone—Anxiety—Mitoxantrone—lymphatic system cancer	0.00275	0.00275	CcSEcCtD
Metolazone—Lethargy—Methotrexate—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Metolazone—Discomfort—Mitoxantrone—lymphatic system cancer	0.00273	0.00273	CcSEcCtD
Metolazone—Anorexia—Carmustine—lymphatic system cancer	0.00272	0.00272	CcSEcCtD
Metolazone—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00269	0.00269	CcSEcCtD
Metolazone—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00266	0.00266	CcSEcCtD
Metolazone—Nausea—Fludarabine—lymphatic system cancer	0.00264	0.00264	CcSEcCtD
Metolazone—Shock—Mitoxantrone—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.0026	0.0026	CcSEcCtD
Metolazone—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00259	0.00259	CcSEcCtD
Metolazone—Urticaria—Bleomycin—lymphatic system cancer	0.00259	0.00259	CcSEcCtD
Metolazone—Anorexia—Vincristine—lymphatic system cancer	0.00259	0.00259	CcSEcCtD
Metolazone—Insomnia—Carmustine—lymphatic system cancer	0.00258	0.00258	CcSEcCtD
Metolazone—Paraesthesia—Carmustine—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Metolazone—Somnolence—Carmustine—lymphatic system cancer	0.00253	0.00253	CcSEcCtD
Metolazone—Anorexia—Mitoxantrone—lymphatic system cancer	0.00252	0.00252	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Metolazone—Decreased appetite—Carmustine—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Metolazone—Insomnia—Vincristine—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Metolazone—Paraesthesia—Vincristine—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Metolazone—Pain—Carmustine—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Metolazone—Constipation—Carmustine—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Metolazone—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Metolazone—Hypersensitivity—Bleomycin—lymphatic system cancer	0.0024	0.0024	CcSEcCtD
Metolazone—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00238	0.00238	CcSEcCtD
Metolazone—Decreased appetite—Vincristine—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Metolazone—Somnolence—Mitoxantrone—lymphatic system cancer	0.00235	0.00235	CcSEcCtD
Metolazone—Feeling abnormal—Carmustine—lymphatic system cancer	0.00235	0.00235	CcSEcCtD
Metolazone—Fatigue—Vincristine—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Metolazone—Asthenia—Bleomycin—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Metolazone—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Metolazone—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Metolazone—Pain—Vincristine—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Metolazone—Constipation—Vincristine—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Metolazone—Pruritus—Bleomycin—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Metolazone—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.0023	0.0023	CcSEcCtD
Metolazone—Fatigue—Mitoxantrone—lymphatic system cancer	0.00228	0.00228	CcSEcCtD
Metolazone—Pancreatitis—Methotrexate—lymphatic system cancer	0.00227	0.00227	CcSEcCtD
Metolazone—Pain—Mitoxantrone—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Metolazone—Constipation—Mitoxantrone—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Metolazone—Abdominal pain—Carmustine—lymphatic system cancer	0.00225	0.00225	CcSEcCtD
Metolazone—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Metolazone—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Metolazone—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00218	0.00218	CcSEcCtD
Metolazone—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Metolazone—Abdominal pain—Vincristine—lymphatic system cancer	0.00215	0.00215	CcSEcCtD
Metolazone—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Metolazone—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Metolazone—Urticaria—Mitoxantrone—lymphatic system cancer	0.0021	0.0021	CcSEcCtD
Metolazone—Hypersensitivity—Carmustine—lymphatic system cancer	0.0021	0.0021	CcSEcCtD
Metolazone—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00209	0.00209	CcSEcCtD
Metolazone—Vomiting—Bleomycin—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Metolazone—Drowsiness—Methotrexate—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Metolazone—Rash—Bleomycin—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Metolazone—Dermatitis—Bleomycin—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Metolazone—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.00205	0.00205	CcSEcCtD
Metolazone—Asthenia—Carmustine—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Metolazone—Hypersensitivity—Vincristine—lymphatic system cancer	0.002	0.002	CcSEcCtD
Metolazone—Epistaxis—Methotrexate—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Metolazone—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Metolazone—Asthenia—Vincristine—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Metolazone—Diarrhoea—Carmustine—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Metolazone—Nausea—Bleomycin—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Metolazone—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00193	0.00193	CcSEcCtD
Metolazone—Asthenia—Mitoxantrone—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Metolazone—Dizziness—Carmustine—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Metolazone—Diarrhoea—Vincristine—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Metolazone—Hepatitis—Methotrexate—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Metolazone—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Metolazone—Vomiting—Carmustine—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Metolazone—Dizziness—Vincristine—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Metolazone—Rash—Carmustine—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Metolazone—Dermatitis—Carmustine—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Metolazone—Headache—Carmustine—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Metolazone—Erythema multiforme—Methotrexate—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Metolazone—Tinnitus—Methotrexate—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Metolazone—Vomiting—Vincristine—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Metolazone—Rash—Vincristine—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Metolazone—Dermatitis—Vincristine—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Metolazone—Headache—Vincristine—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Metolazone—Nausea—Carmustine—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Metolazone—Vomiting—Mitoxantrone—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Metolazone—Rash—Mitoxantrone—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Metolazone—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Metolazone—Chills—Methotrexate—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Metolazone—Headache—Mitoxantrone—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Metolazone—Nausea—Vincristine—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Metolazone—Dysgeusia—Methotrexate—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Metolazone—Nausea—Mitoxantrone—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Metolazone—Back pain—Methotrexate—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Metolazone—Vision blurred—Methotrexate—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Metolazone—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Metolazone—Anaemia—Methotrexate—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Metolazone—Malaise—Methotrexate—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Metolazone—Vertigo—Methotrexate—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Metolazone—Leukopenia—Methotrexate—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Metolazone—Cough—Methotrexate—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Metolazone—Arthralgia—Methotrexate—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Metolazone—Chest pain—Methotrexate—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Metolazone—Discomfort—Methotrexate—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Metolazone—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Metolazone—Anorexia—Methotrexate—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Metolazone—Insomnia—Methotrexate—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Metolazone—Paraesthesia—Methotrexate—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Metolazone—Somnolence—Methotrexate—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Metolazone—Dyspepsia—Methotrexate—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Metolazone—Decreased appetite—Methotrexate—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Metolazone—Fatigue—Methotrexate—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Metolazone—Pain—Methotrexate—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Metolazone—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Metolazone—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Metolazone—Urticaria—Methotrexate—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Metolazone—Abdominal pain—Methotrexate—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Metolazone—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000972	0.000972	CcSEcCtD
Metolazone—Asthenia—Methotrexate—lymphatic system cancer	0.000947	0.000947	CcSEcCtD
Metolazone—Pruritus—Methotrexate—lymphatic system cancer	0.000934	0.000934	CcSEcCtD
Metolazone—Diarrhoea—Methotrexate—lymphatic system cancer	0.000903	0.000903	CcSEcCtD
Metolazone—Dizziness—Methotrexate—lymphatic system cancer	0.000873	0.000873	CcSEcCtD
Metolazone—Vomiting—Methotrexate—lymphatic system cancer	0.000839	0.000839	CcSEcCtD
Metolazone—Rash—Methotrexate—lymphatic system cancer	0.000832	0.000832	CcSEcCtD
Metolazone—Dermatitis—Methotrexate—lymphatic system cancer	0.000831	0.000831	CcSEcCtD
Metolazone—Headache—Methotrexate—lymphatic system cancer	0.000827	0.000827	CcSEcCtD
Metolazone—Nausea—Methotrexate—lymphatic system cancer	0.000784	0.000784	CcSEcCtD
